Related Experiment Video
Updated: Aug 4, 2026

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
Published on: August 28, 2012
EGF/ErbB receptor family in ovarian cancer
N J Maihle1, A T Baron, B A Barrette
1Tumor Biology Program, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
In summary, the EGF/ErbB family of receptor tyrosine kinases has been shown to play a key role in normal ovarian follicle development, and cell growth regulation of the ovarian surface epithelium. Disregulation of these normal growth regulatory pathways, including overexpression and/or mutation of EGFR/ErbB receptor family members, as well as elements of their downstream signalling pathways, have been shown to contribute to the etiology and progression of epithelial ovarian cancer. It is, therefore, not surprising that these gene products, and their related soluble receptor isoforms may have clinical utility as tumor and/or serum biomarkers of disease activity. Moreover, since several of these soluble receptor isoforms have potent growth inhibitory activity, and are naturally occurring in the circulation, they are ideal candidates for the development of novel therapeutics for the treatment of ovarian cancer patients.
Insights
The EGF/ErbB pathway is crucial for ovarian function and cancer. Its dysregulation drives epithelial ovarian cancer, suggesting its members and soluble forms are valuable biomarkers and therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The Epidermal Growth Factor Receptor (EGFR)/ErbB family of receptor tyrosine kinases is vital for normal ovarian follicle development and ovarian surface epithelium cell growth regulation.
- Dysregulation of EGFR/ErbB pathways, including mutations and overexpression, contributes to the development and progression of epithelial ovarian cancer.
Purpose of the Study:
- To investigate the role of the EGF/ErbB pathway in ovarian cancer.
- To explore the potential of EGFR/ErbB family members and their soluble isoforms as biomarkers and therapeutic targets for epithelial ovarian cancer.
Main Methods:
- The study reviews existing literature on the EGF/ErbB pathway in ovarian biology and cancer.
- Analysis of gene expression, mutations, and signaling pathways related to EGFR/ErbB in epithelial ovarian cancer.
Main Results:
- The EGF/ErbB pathway plays a critical role in normal ovarian function and is frequently dysregulated in epithelial ovarian cancer.
- Overexpression or mutation of EGFR/ErbB family members and downstream signaling elements are implicated in ovarian cancer etiology and progression.
Conclusions:
- EGFR/ErbB gene products and their soluble isoforms show potential as clinical biomarkers for disease activity in epithelial ovarian cancer.
- Soluble receptor isoforms exhibiting growth inhibitory properties are promising candidates for novel ovarian cancer therapeutics.
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Regulation of Angiogenesis and Blood Supply
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

